晚期头颈癌放化疗后咬肌与翼内肌辐射剂量与牙关紧闭的关系
研究纳入83例接受放化疗及调强放疗的晚期头颈癌患者,治疗前及治疗后13周测量最大切牙间距,17%出现牙关紧闭(最大切牙间距≤35 mm)。同侧翼内肌与咬肌剂量参数均可预测牙关紧闭,加入基线最大切牙间距显著改善正常组织并发症概率模型。
要点
- 83例晚期头颈癌患者放化疗后13周牙关紧闭发生率为17%。
- 同侧翼内肌和咬肌剂量参数均可预测牙关紧闭,平均剂量及中间剂量体积参数尤为相关。
- 加入基线最大切牙间距显著改善正常组织并发症概率模型,最优截断值为翼内肌平均剂量58 Gy、咬肌平均剂量22 Gy、基线最大切牙间距46 mm。
核心结论
- 同侧翼内肌剂量、同侧咬肌剂量及基线最大切牙间距均为牙关紧闭预测的临床相关参数。
研究设计与样本
- 研究纳入83例接受放化疗及调强放疗的晚期头颈癌患者,于治疗前及治疗后13周测量最大切牙间距,牙关紧闭定义为最大切牙间距≤35 mm。
- 采用 logistic 回归模型拟合同侧咬肌与同侧翼内肌剂量参数及基线最大切牙间距,并生成风险分类树以获得最优截断值和风险分组。
主要发现
- 83例患者中17%出现牙关紧闭。
- 同侧翼内肌与同侧咬肌因解剖邻近,剂量水平高度相关。
- 同侧翼内肌和同侧咬肌剂量参数均可预测牙关紧闭,尤其是平均剂量和中间剂量体积参数。
- 加入基线最大切牙间距后,正常组织并发症概率模型显著改善。
- 最优截断值为翼内肌平均剂量58 Gy、咬肌平均剂量22 Gy、基线最大切牙间距46 mm。
关键数值与推荐
- 牙关紧闭定义为最大切牙间距≤35 mm。
- 最优截断值:翼内肌平均剂量58 Gy,咬肌平均剂量22 Gy,基线最大切牙间距46 mm。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We studied the relationship between trismus (maximum interincisor opening [MIO] ≤35 mm) and the dose to the ipsilateral masseter muscle (iMM) and ipsilateral medial pterygoid muscle (iMPM). METHODS: Pretreatment and post-treatment measurement of MIO at 13 weeks revealed 17% of trismus cases in 83 patients treated with chemoradiation and intensity-modulated radiation therapy. Logistic regression models were fitted with dose parameters of the iMM and iMPM and baseline MIO (bMIO). A risk classification tree was generated to obtain optimal cut-off values and risk groups. RESULTS: Dose levels of iMM and iMPM were highly correlated due to proximity. Both iMPM and iMM dose parameters were predictive for trismus, especially mean dose and intermediate dose volume parameters. Adding bMIO, significantly improved Normal Tissue Complication Probability (NTCP) models. Optimal cutoffs were 58 Gy (mean dose iMPM), 22 Gy (mean dose iMM) and 46 mm (bMIO). CONCLUSIONS: Both iMPM and iMM doses, as well as bMIO, are clinically relevant parameters for trismus prediction.
引用
- Kraaijenga SA, Hamming-Vrieze O, Verheijen S, et al. Radiation dose to the masseter and medial pterygoid muscle in relation to trismus after chemoradiotherapy for advanced head and neck cancer. Head Neck. 2019. PMID: 30652390. doi:10.1002/hed.25573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。